IGC Pharma, Inc. 8-K

What Happened

• IGC Pharma, Inc. (IGC) filed a Current Report on Form 8-K on July 14, 2026 (Item 7.01) to furnish an updated investor presentation dated July 2026. The presentation is included as Exhibit 99.1 and is incorporated by reference.
• The company says it may use the presentation, in whole or in part and with updates, in meetings with investors, analysts, potential partners and at conferences. The presentation is summary information, speaks only as of the 8-K date, and the company is not obligated to update it except as required by law.
• The filing includes typical forward-looking statement disclaimers covering risks such as enrollment and timing for the CALMA Phase 2 trial of IGC-AD1, safety and efficacy, regulatory approvals, commercialization, market acceptance and valuation-related cautions.

Key Details

• Filing date: July 14, 2026 (Current Report on Form 8-K).
• Exhibit furnished: 99.1 — IGC Pharma Investor Presentation, dated July 2026 (also included Inline XBRL cover page as Exhibit 104).
• Clinical program referenced: CALMA Phase 2 trial of IGC-AD1 (timing, enrollment and outcome risk highlighted).
• Presentation is summary-only and may be modified; contains forward-looking statements and associated risk disclosures.

Why It Matters

• For investors, this filing provides the company’s latest public presentation and messaging about its strategy and clinical program (not new financial results or leadership changes).
• The inclusion of forward-looking statements and explicit callouts about the CALMA Phase 2 trial reminds investors that timing, enrollment and trial outcomes remain key risks that could affect value.
• This is a Regulation FD disclosure—useful for tracking company communications and investor materials but not a standalone operational or financial update.